Shanghai Juntuo Biomedical Technology

Shanghai Juntuo Biomedical Technology is a clinical-stage biotechnology company and a subsidiary of Junshi Biosciences, specializing in the development of vaccines and anti-infective therapies. The company gained significant prominence for its role in developing VV116 (Deuremidevir hydrobromide), an oral antiviral for COVID-19, and various vaccine candidates including recombinant protein and mRNA-based options. Based in Shanghai, Juntuo Bio leverages advanced technology platforms to address urgent public health needs and infectious disease challenges. Its pipeline includes several high-profile programs targeting viral pathogens, supported by the extensive R&D infrastructure of its parent company.